Kazia Therapeutics: Diverse Cancer Pipeline Still Needs A Major Catalyst [Seeking Alpha]
Kazia Therapeutics Limited - American Depositary Shares (KZIA)
US:NASDAQ Investor Relations:
kaziatherapeutics.com
Company Research
Source: Seeking Alpha
Paxalisib is also being explored across CNS tumors and TNBC, giving Kazia broad oncology optionality but limited near-term validation. NDL2 and SETDB1 add differentiated immuno-oncology platforms, though both remain preclinical and remain mostly speculative. Fortunately, KZIA has a healthy cash runway into 2029, which reduces any near-term dilution risks. But, on balance, I feel KZIA's interesting assets and speculative M&A potential aren't worth buying at these levels. Vladislav Stepanov/iStock via Getty Images Kazia Therapeutics Limited ( KZIA ) is a clinical-stage oncology company that develops several programs. Their lead asset is Paxalisib, in Phase 2/3 in glioblastoma (GBM), with results in GBM showing meaningful concurrent-control survival data. Paxalisib is also studied in
Show less
Read more
Impact Snapshot
Event Time:
KZIA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
KZIA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
KZIA alerts
High impacting Kazia Therapeutics Limited - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
KZIA
News
- Novogen (KZIA) is now covered by Laidlaw. They set a "buy" rating and a $25.00 price target on the stock.MarketBeat
- Kazia Therapeutics Strengthens Scientific Leadership with Appointment of Dr. Sudha Rao as Chief Scientific Officer to Lead Next-Generation Oncology Platform [TheStreet.com]TheStreet.com
- Kazia Therapeutics Strengthens Scientific Leadership with Appointment of Dr. Sudha Rao as Chief Scientific Officer to Lead Next-Generation Oncology PlatformPR Newswire
- Kazia Therapeutics Expands Oncology Platform with First-in-Class SETDB1 Inhibitor Drug Development Platform [Yahoo! Finance]Yahoo! Finance
- Kazia Therapeutics Expands Oncology Platform with First-in-Class SETDB1 Inhibitor Drug Development Platform [TheStreet.com]TheStreet.com
KZIA
Sec Filings
- 4/27/26 - Form 6-K
- 4/15/26 - Form 424B3
- 4/15/26 - Form 424B3
- KZIA's page on the SEC website